Improved prognosis with additional medium ‐dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults

This study was the first to reveal the efficacy of the addition of medium‐dose VP16 to CY/TBI in high‐risk ALL. To establish new myeloablative conditioning regimens including VP16, a large‐scale prospective study is necessary. This article is protected by copyright. All rights reserved.

Source: American Journal of Hematology - October 6, 2017 Category: Hematology Authors: Yasuyuki Arai, Tadakazu Kondo, Akio Shigematsu, Junji Tanaka, Kazuteru Ohashi, Takahiro Fukuda, Michihiro Hidaka, Naoki Kobayashi, Koji Iwato, Toru Sakura, Makoto Onizuka, Yukiyasu Ozawa, Tetsuya Eto, Mineo Kurokawa, Kaoru Kahata, Naoyuki Uchida, Yoshiko Tags: Research Article Source Type: research